8-KEarnings & ResultsExhibits & Filings

ELI LILLY & Co 8-K Report, Financial Results (Jan 7, 2014)

Filed January 7, 2014For Securities:LLY

Summary

Eli Lilly and Company (LLY) filed an 8-K on January 7, 2014, to provide updated financial guidance for 2013 and initial financial guidance for 2014. The company also announced that it held a teleconference for analysts and media to discuss this guidance, which was webcast on their website. This filing is primarily focused on forward-looking statements regarding the company's financial performance expectations. Investors should note that Lilly often uses non-GAAP financial measures, such as non-GAAP earnings per share, to provide a clearer view of ongoing operations. These measures exclude items that are typically unpredictable and can significantly impact reported results. The company believes these non-GAAP metrics are valuable for investors to assess operational trends and facilitate meaningful comparisons, while management also uses them for internal performance evaluation and resource allocation.

Key Highlights

  • 1Announcement of 2013 financial guidance update.
  • 2Issuance of initial financial guidance for the fiscal year 2014.
  • 3Holding of an analyst and media teleconference on January 7, 2014, to discuss financial guidance.
  • 4Webcast of the teleconference on the company's website.
  • 5Use of non-GAAP financial measures, such as non-GAAP EPS, highlighted for investor insight.
  • 6Explanation of why non-GAAP measures are used: to exclude unpredictable, high-impact items and evaluate ongoing operations.
  • 7Cautionary note that non-GAAP measures should be considered in addition to, not as a substitute for, GAAP measures.

Frequently Asked Questions

The main purpose of this 8-K filing is to provide updated financial guidance for Eli Lilly's 2013 performance and to announce their initial financial guidance for the upcoming fiscal year 2014. It also serves to inform the public about a related teleconference held for analysts and media.

This 8-K filing primarily announces that financial guidance is being provided and that a press release (Exhibit 99.1) contains the details. The 8-K itself does not list the specific numerical guidance but refers investors to the attached press release and the teleconference for that information.

Non-GAAP financial measures, such as non-GAAP earnings per share (EPS), are financial metrics that exclude certain items from GAAP (Generally Accepted Accounting Principles) results. Lilly uses them because they exclude items that are typically highly variable, difficult to predict, and can have a substantial impact on reported earnings. The company believes these measures offer investors a more useful view of ongoing operations, help in making period-over-period comparisons, and identify operating trends.

Investors should consider these non-GAAP measures as supplementary information to, and not as a replacement for or superior to, financial performance measures prepared in accordance with GAAP. They provide additional insight but should be analyzed alongside the standard GAAP financial statements.